- Home
- DXCM vs ONC Comparison
DXCM vs ONC Comparison
Compare DXCM & ONC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DXCM
- ONC
- Stock Information
- Founded
- DXCM 1999
- ONC 2010
- Country
- DXCM United States
- ONC Switzerland
- Employees
- DXCM N/A
- ONC N/A
- Industry
- DXCM Medical/Dental Instruments
- ONC Biotechnology: Pharmaceutical Preparations
- Sector
- DXCM Health Care
- ONC Health Care
- Exchange
- DXCM Nasdaq
- ONC Nasdaq
- Market Cap
- DXCM 31.7B
- ONC 34.8B
- IPO Year
- DXCM 2005
- ONC N/A
- Fundamental
- Price
- DXCM $68.51
- ONC $316.85
- Analyst Decision
- DXCM Strong Buy
- ONC Strong Buy
- Analyst Count
- DXCM 16
- ONC 10
- Target Price
- DXCM $97.19
- ONC $350.00
- AVG Volume (30 Days)
- DXCM 4.5M
- ONC 223.4K
- Earning Date
- DXCM 10-30-2025
- ONC 11-06-2025
- Dividend Yield
- DXCM N/A
- ONC N/A
- EPS Growth
- DXCM N/A
- ONC N/A
- EPS
- DXCM 1.43
- ONC N/A
- Revenue
- DXCM $4,300,800,000.00
- ONC $4,562,002,000.00
- Revenue This Year
- DXCM $17.01
- ONC $887.89
- Revenue Next Year
- DXCM $15.36
- ONC $22.45
- P/E Ratio
- DXCM $48.41
- ONC N/A
- Revenue Growth
- DXCM 9.30
- ONC 47.33
- 52 Week Low
- DXCM $57.52
- ONC $170.99
- 52 Week High
- DXCM $93.25
- ONC $355.30
- Technical
- Relative Strength Index (RSI)
- DXCM 46.58
- ONC 46.40
- Support Level
- DXCM $66.42
- ONC $306.00
- Resistance Level
- DXCM $72.07
- ONC $320.35
- Average True Range (ATR)
- DXCM 2.02
- ONC 8.16
- MACD
- DXCM 0.62
- ONC -1.72
- Stochastic Oscillator
- DXCM 59.83
- ONC 34.10
About DXCM DexCom Inc.
DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.
About ONC BeiGene Ltd. American Depositary Shares
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeOne is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeOne runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeOne's revenue.